Korro Bio
The Associate Director, Clinical QA provides hands-on quality oversight for Korro Bio's clinical and nonclinical programs, ensuring compliance with GCP, GLP, and GCLP standards. This individual contributor role involves planning and conducting audits of CROs, laboratories, and investigator sites while serving as a quality partner to study teams. The position requires risk-based judgment to protect patient safety, participant rights, and data integrity across global clinical development programs.
Korro Bio is a biotechnology company developing precision RNA‑editing therapeutics that edit a single letter on RNA to modulate biological pathways. Their mission is to translate this platform into genetic-medicine solutions for complex, prevalent diseases by advancing a focused therapeutic pipeline. The company emphasizes moving its science toward patient‑facing programs and resources (for example, work relevant to AATD) to deliver targeted, durable treatments.
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
4 days ago
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability
4 days ago
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Jan 16, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Korro Bio.
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)
4 days ago